LIVN Price Prediction Next Week
Analysis and Insights
News Sentiment and Analyst Ratings:
LivaNova (LIVN) has seen a series of analyst downgrades recently. Barclays lowered its price target to $56 from $58, maintaining an Equal Weight rating, while Mizuho, Stifel, and Baird also reduced their targets to $60. Wolfe Research downgraded the stock to Peer Perform from Outperform, reflecting growing concerns about the company's outlook.
Technical Analysis:
The stock is currently trading at $40.43, with bearish momentum indicated by its RSI_14 of 39.14 and a negative MACD. The Fibonacci support level at $36.37 is a key target if the stock breaks below its current levels.
Fibonacci Levels:
The Fibonacci levels suggest resistance at $42.38 and support at $36.37, with the pivot point at $39.37.
Conclusion:
Based on the bearish technical indicators and negative analyst sentiment, the stock is expected to decline to $36.37 next week.
Recommendation: Sell LIVN at the current price target of $36.37.
LIVN Similar Chart Price Prediction
The price of LIVN is predicted to go up -8.89%, based on the high correlation periods with MPU. The similarity of these two price pattern on the periods is 98.35%.
LIVN
MPU
Down: -8.89%Similarity: 98.35%
LIVN Revenue Forecast
LIVN EPS Forecast
LIVN FAQs
What is LIVN revenue forecast for next quarter？
What is LIVN eps forecast for next quarter？
LIVN VS S&P500
LivaNova continues to enjoy a large footprint in the heart-lung machine market, which comes with the sale of consumable oxygenators.
If vagus nerve stimulation proves effective for sleep apnea, this could be a large growth opportunity for LivaNova.
LivaNova has developed expertise in smaller, more niche markets, which helps insulate the business from more intense competition seen elsewhere in medtech.
LIVN Analyst's Forecast
Matt Miksic
Barclays
Hold
2025-03-07
Price Target
$58 → $56
Upside
+42.97%
Barclays lowered the firm's price target on LivaNova to $56 from $58 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect its 2025 guidance and recent commentary.
Mike Matson
Needham
Strong Buy
2024-11-25
Price Target
$75
Upside
+44.93%
David Rescott
Baird
Buy
2024-10-31
Price Target
$66 → $72
Upside
+39.48%
